169590-41-4

Basic information

• Product Name: Deracoxib
• Synonyms: Benzenesulfonamide, 4-3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl-;4-(3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;Deracoxib [usan];Deramaxx;Sc 46;Sc 59046;Unii-vx29jb5xwv;4-[5-(3-Fluoro-4-Methoxyphenyl)-3-(difluoroMethyl)-1H-pyrazol-1-yl]benzenesulfonaMide
• CAS NO: 169590-41-4
• Molecular Formula: C₁₇H₁₄F₃N₃O₃S
• Molecular Weight: 397.38
• EINECS: 1308068-626-2
• Mol File: 169590-41-4.mol

Chemical Properties

• Melting Point: 159-161°
• Boiling Point: 575.5°C at 760 mmHg
• Flash Point: 301.9°C
• Appearance: /
• Density: 1.48
• Vapor Pressure: 3E-13mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: 2-8°C
• Solubility: Acetonitrile (Slightly), DMSO (Slightly)
• PKA: 9.69±0.10(Predicted)
• CAS DataBase Reference: Deracoxib(CAS DataBase Reference)
• NIST Chemistry Reference: Deracoxib(169590-41-4)
• EPA Substance Registry System: Deracoxib(169590-41-4)

Safety Data

• Hazardous Substances Data: 169590-41-4(Hazardous Substances Data)

Usage

Uses

Used in Veterinary Medicine:
Deracoxib is used as an anti-inflammatory agent for the treatment of osteoarthritis in dogs. It acts as a selective COX-2 inhibitor, helping to control pain and inflammation without causing significant gastrointestinal side effects at low doses.
Used in Pain Management:
In addition to its use in treating osteoarthritis, Deracoxib is also utilized for managing pain in dogs. Its selective COX-2 inhibition allows for effective pain relief with a lower risk of gastrointestinal complications compared to some other NSAIDs.
Used in Inflammation Control:
Deracoxib is employed as an inflammation control agent, helping to reduce the inflammation associated with various conditions in dogs. Its selective COX-2 inhibition makes it a suitable choice for controlling inflammation while minimizing potential side effects.

Veterinary Drugs and Treatments

Deracoxib is indicated for the treatment of post-operative pain (higher dose, 7 day maximum), and for the treatment of pain and inflammation associated with osteoarthritis (lower dose, ongoing dosing) in dogs. Like piroxicam, deracoxib is of interest in adjunctive treatment of transitional cell carcinoma of the bladder; investigations into this use are ongoing.

InChI:InChI=1/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)

Upstream product

• 17852-52-7 4-hydrazinobenzene-1-sulfonamide hydrochloride 
• 321-28-8 1-fluoro-2-methoxybenzene 
• 170570-77-1 4,4-difluoro-1-(3-fluoro-4-methoxyohenyl)-butane-1,3-dione 
• 288-13-1 NH-pyrazole 
• 454-31-9 ethyl difluoroacetate 
• 455-91-4 1-(3-fluoro-4-methoxyphenyl)ethanone 

Relevant articles and documents

Copper-Catalyzed Reductive Ring-Cleavage of Isoxazoles: Synthesis of Fluoroalkylated Enaminones and Application for the Preparation of Celecoxib, Deracoxib, and Mavacoxib

We have identified a new reactivity of copper/diamine catalysis for the reductive ring-cleavage of isoxazoles to yield fluoroalkylated enaminones. This protocol has the advantage of using commercially available reagents, ease of setting up, broad tolerance of functionality, and is regiospecific and free of defluorination and reduction of reducible functional groups. The utility was demonstrated by a one-step, regioselective synthesis of fluoroalkylated pyrazole-based drugs such as celecoxib, deracoxib, and mavacoxib.

Preparation method of Deracoxib

The invention discloses a preparation method of Deracoxib, and belongs to the field of Deracoxib preparation. The preparation method of Deracoxib disclosed by the invention comprises the following steps: (1) taking methane chloride as a reaction solvent, and reacting 2-fluoroanisole with acetylchloride under the effect of acid so as to obtain 3-fluoro-4-methoxyacetophenone; (2) taking methane chloride as a reaction solvent, and reacting 3-fluoro-4-methoxyacetophenone with ethyl difluoroacetate under the effect of alkaline so as to obtain 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)-1,3-butanedione; and (3) under the existence of an ethyl alcohol solvent, reacting 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)-1,3-butanedione with para-sulfamine phenylhydrazine or salt thereof so as to obtain Deracoxib. According to the preparation method of Deracoxib disclosed by the invention, dichloromethane is used as a solvent, the toxicity of the solvent is low, the cost of the solvent is lower than thatof methyl tertiary butyl ether, and the production cost is obviously reduced on the premise of guaranteeing the yield.

COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR

The present invention provides a combination of a selective NMDA NR2B antagonist and a COX-2 inhibitor for the treatment or prevention of pain or nociception.

METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula (I) wherein A, R and R are as described in the specification.

Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor

This invention relates to the use of a tocolytic agent or agents in combination with selective cyclooxygenase-2 inhibitors of Formula (II) or a pharmaceutically-acceptable salt or derivative thereof for preparing a medicament for maintaining circulation through fetal ductus arteriosus during treatment or prevention of preterm labor in a subject in need of such treatment or prevention.

Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation

The present invention provides the use of a COX-2 inhibitior and an NK-1 receptor antagonist for the treatment or prevention of inflammatory disorders.

THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS

The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises

Method for the treatment and prevention of cachexia

Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.

Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor

The present invention provides a method for the treatment or prophylaxis of COX-2-mediated conditions in patients who are at risk of developing thromboembolic events which comprises administering to said patient a therapeutically or prophylactically effective amount of a COX-2 selective inhibitor and a cardiovascular protective amount of a thromboxane inhibitor, as well as compositions therefor.

Combination therapy in the prevention of cardiovascular disorders

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders.